The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

Study Identifier:
C06-002
ClinicalTrials.gov Identifier:
NCT00438789
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: eculizumab
Date
N/A - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: eculizumab
Date
N/A - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Trial Locations

Location
Status
Location
Anthony Botti
Livingston, New Jersey, United States
Status
N/A